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Abstract: Renal insufficiency leads to uremia, a complicated syndrome. It thus becomes vital 
to reduce waste metabolites and regulate water and electrolytes in kidney failure. The most 
common treatment of this disease is either dialysis or transplantation. Although these treatments 
are very effective, they are extremely costly. Recently artificial cells, microencapsulated live 
bacterial cells, and other cells have been studied to manage renal failure metabolic wastes. The 
procedure for microencapsulation of biologically active material is well documented and offers 
many biomedical applications. Microencapsulated bacteria have been documented to efficiently 
remove urea and several uremic markers such as ammonia, creatinine, uric acid, phosphate, 
potassium, magnesium, sodium, and chloride. These bacteria also have further potential as 
biotherapeutic agents because they can be engineered to remove selected unwanted waste. This 
application has enormous potential for removal of waste metabolites and electrolytes in renal 
failure as well as other diseases such as liver failure, phenylketonuria, and Crohn’s disease, to 
name a few. This paper discusses the various options available to date to manage renal failure 
metabolites and focuses on the potential of using encapsulated live cells as biotherapeutic agents 
to control renal failure waste metabolites and electrolytes.
Keywords: renal failure, microencapsulation, artificial cells, oral administration, bacterial cells, 
metabolites, electrolytes, polymeric membrane
Renal failure, waste metabolites, and electrolytes
Kidney disease is among the most common diseases afflicting over 20 million 
Americans. Over 90,000 fatalities occur every year due to kidney diseases. Nearly 
350,000 Americans suffer from end-stage renal disease (ESRD), the final stage in 
chronic renal failure. Each year, the number of patients with chronic kidney failure 
increases by an astounding 11%!
Kidney malfunction results from a reduction in glomerular filtration rate and 
causes an increase in concentration of waste metabolites that are measurable in 
blood.1 For example, in human waste, metabolites such as blood urea nitrogen (BUN) 
increase from 15 mg/dl to 100–300 mg/dl, serum creatinine increase from 1 mg/dl to 
10–25 mg/dl, and considerable amounts of uric acid are also known to accumulate.2–4 
More specifically, in uremia, the concentration of uremic toxins such as ammonia, 
urea, phenols, indoles, and guanidino compounds such as n-methyl guanidine (NMG) 
and guanidino succinic acid (GSA) are significantly altered with accompanying 
abnormalities in acid-base equilibrium, and retention of electrolytes and water reten-
tion.5,6 The accumulation of uremic toxins in patients suffering from renal insuf-
ficiency inhibits various physiologic and biochemical functions thereby manifesting Biologics: Targets & Therapy 2009:3 234
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toxic symptoms. For example, hyperammonium can lead 
to mental retardation and, in severe cases, coma.7 Water 
retention causes edema and as the concentration of hydrogen 
ions increases, acidosis develops. If untreated, acidosis 
and uremia can cause coma and eventually result in death. 
Thus, the high concentrations of these substances in have 
to be lowered before their increased level results in severe 
disturbances of metabolic pathways. Thus, as the kidney is 
accountable for the elimination of wastes from the blood, 
any damage, either from an accident or disease that causes 
renal insufficiency in the patient, can lead to a build-up of 
toxic waste in the body. Removing urea and ammonia from 
the plasma is not only necessary in kidney failure,1,8–11 but 
also in other diseases like liver failure.1,8,12,13
Treatment options for managing 
renal failure waste metabolites  
and electrolytes
Effective treatments for renal failure and elucidation of 
uremia have traditionally been dialysis or a kidney transplant. 
Only 15% of the world’s uremic patients can afford dialysis 
treatment, as it is a very expensive, time-consuming, and 
complicated technique.4,14–16 About 80,000 Americans on 
dialysis die of various complications each year. As a result of 
the global shortage of kidney donors for kidney transplants, 
high costs linked with transplant surgery, and high probability 
of organ rejection, most patients worldwide have very few 
options for effective treatment after kidney failure. Over 
27,000 patients are on waiting lists for kidney transplants 
each year and only about 11,000 receive transplants. There is 
great urgency in the quest for an unconventional, affordable 
therapy for patients who cannot afford expensive dialysis 
or kidney transplant to keep them alive. Medical scientists 
are attempting to research and develop an innovative, low 
expense therapy that goes beyond the traditional treatment 
for reinstated kidney function. Several alternatives have been 
considered.4,9,10,17–23
In the past few decades, molecular technology has greatly 
influenced the course of biomedical research. Prospective 
medical applications include discovering the genetic basis 
for certain ailments, gene therapy, and production of effectual 
therapeutic agents. A distinguished researcher, Dr Kolff, 
found that creatinine, uric acid, and other nitrogenous wastes 
can easily be removed from plasma with oral sorbents.20 With 
the use of oral absorbents, the interval between hemodialysis 
treatments could be delayed considerably.21 Some researchers 
have proposed and confirmed the use of the co-immobilized 
enzyme, urease, which breaks down urea into ammonia 
which is then eliminated by adsorbents.9,10,17,18 However, 
some scientists report that the currently available ammonia 
adsorbent does not have adequate adsorbent capacity.16,19
An alternative approach has been suggested that would be 
cheaper and more convenient for the patient: an oral therapy 
containing a combination of adsorbents, osmotic agents, 
and ion-exchange agents.24 Chang examined the potential 
of combining a microencapsulated enzyme, urease, with an 
ammonium ion adsorbent, zirconium phosphate, to remove 
urea in vitro. Urease broke down urea to ammonium ions 
which were then adsorbed onto zirconium phosphate. This 
system had the ability to delay the onset of dialysis therapy in 
patients with partial kidney function and may even decrease 
the treatment times for dialysis in some patients.25 Oxystarch 
and urease–zirconium phosphate have been demonstrated to 
be successful in removing urea and ammonia.2,4 However, 
the amount required is too large to allow for use in routine 
treatment of the patients.26 and also markedly small amount 
of urea removal have been reported in vivo, particularly at a 
neutral pH.6,13,15,19,23,27–30
In another approach, a microencapsulated multienzyme 
system that converts urea and ammonia into essential amino 
acids was investigated.13,18,19,28 However, this encapsulated 
multienzyme system had an inadequate urea and ammonia 
conversion rate.31 Thus, the desire for an efficient system 
for urea and ammonia removal is apparent.32 It is essential 
to develop novel approaches to replace kidney function that 
majority of the world can afford. One prospect involves 
creation of a ‘bioartificial/bionic kidney’ in which normal 
renal function are performed by tissue culture cells implanted 
in a hollow fiber or mesh matrix.33 In spite of great potential 
for the bionic kidney, it, too, will be exorbitantly expensive 
and will require extremely skilled personnel. In a recent 
article in the April 2007 issue of The FASEB Journal, Cody 
Mooneyhan described the use of puffer fish gills to excrete 
ammonia at the molecular level using Rh proteins and 
reported that the protein which excretes ammonia through 
puffer fish gills was found to be similar to human Rh blood 
proteins. Thus, by targeting human Rh proteins, people with 
damaged livers and kidneys can eliminate toxic ammonia 
from their bloodstream.34
Stem cells are unspecialized precursor cells that can 
self-renew and develop into specialized cells. Stem cell 
researchers are working towards the ultimate goal of 
production of a new kidney as a mean of kidney therapy. 
This is a complicated challenge since the kidney is made 
from several specialized cell types, each with its own Biologics: Targets & Therapy 2009:3 235
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unique function. Another strand of biotechnology that 
holds promise in the treatment of kidney failure is the use 
of bioencapsulated living cells.35 It is possible to geneti-
cally engineer nonpathogenic bacterial cells for a desired 
metabolic activity and they then serve as outstanding 
therapeutic agents. The idea of administering encapsulated 
bacterial enzymes to break down toxic substances was 
first introduced in Finland in 1978.32,36 In one proposed 
system, selected bacteria converted nitrogeneous waste 
products into nontoxic chemicals that could be recycled 
within the subject.24,37 Thus, several approaches to treat 
renal insufficiency have been proposed.4,13,15,16,23,29,30,38–40 
Some researchers suggest the use of microencapsulated 
urease to convert urea into ammonia that is subsequently 
removed by coencapsulated ammonia adsorbent9,14 or as 
mentioned above, some researchers propose administering 
microencapsulated multienzyme complex to convert urea 
and ammonia into essential amino acids9,15,39,28 or using 
lyophilized urea-utilizing soil bacteria.41,42
Microencapsulated cells have also been reported to be 
successful in other medical complications. For example, 
the microencapsulated islet cells were found to remain 
viable and secreted insulin to regulate glucose levels in 
diabetic rats. This approach prevented immunorejection 
after implantation.43 Similarly, microencapsulated hepato-
cytes have been shown to lower the high serum bilirubin 
level to 6.00 ± 1.00 mg/100 mL twenty days after implanta-
tion in Gunn rats. Analysis showed that this was achieved 
because the implanted encapsulated hepatocytes carried out 
the function of the liver in the conjugation of bilirubin44,45 
and enhanced the survival time of fulminant hepatic failure 
in rats.45 Recent reports by another group also support this 
finding.46 The possibility of using live selected bacteria, 
preferably Bacillus pasteurii or Lactobacillus sporogenes, 
in vivo to treat renal, hepatic and gastrointestinal diseases 
by eliminating toxins and other metabolic waste products 
has been proposed.7 The study also showed that a probiotic 
containing either B. pasteurii and L. sporogenes, or both, 
are capable of increasing survival in otherwise untreated 
uremic rats.
In another approach to alleviate uremia or renal 
insufficiency, a mixture comprising of one or more selected 
bacteria (which converts nitrogenous waste into nontoxic 
compounds in vivo), along with one or more of the following: 
a prebiotic, ammoniaphilic bacteria with high urease activity, 
and/or sorbents with specific adsorption affinities for uremic 
toxins and inorganic phosphate along with a water sorbent 
have been proposed.43 A series of probiotics (foods that 
contain ‘beneficial’ bacteria, such as Lactobacillus), along 
with oral adsorbents like charcoal and locust bean gum, have 
also been explored and tested in subjects as a potential oral 
renal replacement therapy.47
There have been rapid advances in molecular biology 
that have resulted in the use of genetically engineered 
microorganisms for remedial purposes. Genetically 
engineered cells that were incapable of surviving passage 
through the gastrointestinal tract have made it successfully 
to their destination by the use of artificial cell microcapsules. 
Microorganisms can be engineered to remove unwanted 
molecules from the body as they travel through the intestine 
and are finally excreted in the stool without being retained 
in the body. This idea has great prospects and it is likely that 
soon trained bacteria will act as a substitute for the kidney 
and liver and perform most endocrine functions.
Microencapsulated genetically modified cells have been 
reported to have enormous potential for the elimination of 
certain metabolites such as urea in kidney failure, ammonia 
in liver failure, and amino acids such as phenylalanine in 
phenylketonuria and other innate errors of metabolism.48 
In addition, genetically engineered encapsulated Erwinia 
herbicola cells have demonstrated an ability to convert 
ammonia into usable amino acids for the cells before being 
eliminated via the bowel. Microencapsulated genetically 
engineered Escherichia coli DH5 cells have also been shown 
to be effective in removal of urea and ammonia in an in vitro 
system and in a uremic rat animal model.49,50 Despite the 
research in this field, we are still looking for a suitable urea 
and ammonia removal system. The most promising approach, 
using microencapsulated bacterial cells for renal therapy, is 
discussed extensively in this article.
Potential of live free  
and encapsulated cells  
in renal failure
About forty years ago, Malchesky first suggested that certain 
natural strains of microorganisms were exceptionally suc-
cessful in degrading urea in vitro. He also reported that these 
microbes can be trained to enhance their ability to degrade 
urea and other compounds normally excreted in urine.51 Soon 
after, Setala pioneered the notion of oral delivery of lyophi-
lized bacteria harvested from soil.36 These bacteria were 
extremely effective in degrading nonprotein nitrogenous 
compounds in uremic patients.
Later, in the 1990s, Chang established the concept of 
delivery of microencapsulated genetically modified bacteria to Biologics: Targets & Therapy 2009:3 236
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63.0 ± 26 mg/dl, respectively compared to a previous 
concentration of 99.0 ± 46 mg/dl. This reduction of 38% 
and 37%, respectively indicated that B. pasteurii and 
L. sporogenes administered orally as dietary supplements 
could metabolize urea in vitro.7
Alternatively, the use of probiotics in removal of plasma 
urea has also been explored. Suspension of L. delbrueckii 
in uremic plasma reduced the urea nitrogen levels from 
51.5 ± 5.2 mg/dL to 44.3 ± 3.9 mg/dL (p = 0.02) after 24 hours 
in vitro. With microencapsulation of Lactobacillus (inside 
semipermeable alginate–polylysine–alginate polymeric 
membrane [APA]), further lowering of urea nitrogen levels 
was achieved (35.4 ± 0.8 mg/dL, p = 0.03) at 24 hours. It is 
proposed that expression of certain enzymes could be induced 
in L. delbrueckii which can then effectively lower plasma 
urea60 and possibly other waste metabolites in uremia.
Recently, Chang and Prakash proposed the use of 
microencapsulated genetically engineered bacterial cells to 
remove plasma urea and ammonia. In vitro, 40.00 ± 8.60 g 
of APA-encapsulated bacteria were shown to remove 
87.89 ± 2.25% of the plasma urea within 20 minutes and 
99.99% of urea in 30 minutes. Bacterial cells were reported to 
use urea for their metabolic nitrogen requirement and did not 
produce ammonia as a by-product.57 Thus, results demonstrate 
that this biotechnological approach is 10–30 times more com-
petent in eliminating urea and ammonia than the currently 
available traditional approaches.31
In a different study, surgical renal failure induced in rats 
(removal of one kidney and the partial ligation of the other) 
resulted in a substantial increase in blood urea levels without 
noticeable disturbances in water and electrolyte balances. 
A drop in the plasma urea level from 52.08% ± 2.06% mg 
to 9.10% ± 0.71% mg was observed upon daily oral 
administration of log phase microencapsulated genetically 
engineered E. coli DH5 cells for 21 days. The plasma urea 
level was maintained within the normal range during the 
entire treatment period. The urea levels became elevated 
once the treatment was stopped.61,62 It is hypothesized that 
during the passage of microcapsules through the gastroin-
testinal tract, small molecules from the body, such as urea, 
ammonia, amino acids, etc., diffuse into the microcapsules 
where they are metabolized by genetically engineered cells 
for their nitrogen source before being excreted in the stool. 
This results in lowering the high plasma urea level to standard 
levels in uremic rats with induced kidney failure.32 Since 
urea levels returned to pretreatment values upon stopping the 
treatment, it is implied that there is no significant retention 
of E. coli DH5 cells in the intestine.63
degrade nitrogenous waste products in uremic patients in vivo 
as well as in vitro. The procedures for microencapsulation of 
biologically active materials are well recognized and offer 
various biomedical applications.9,11,13,17,22,31,52–54 Thus, the 
possibility of using bacterial cells to treat kidney failure has 
been explored for over four decades. Research in the field 
of artificial cell microcapsules revealed the possibility of 
oral administration of live genetically engineered cells for 
therapeutic functions.32,55 This concept has direct relevance 
for the use of encapsulated bacterial oral therapy in renal 
failure and liver failure,32 physiologically responsive gene 
therapy,56,57 and somatic gene therapy.58,59 Modern techno-
logical advances in molecular biology have resulted in the 
accessibility of nonpathogenic genetically engineered micro-
organisms that can effectively use uremic metabolites for cell 
growth. This paper is an overview of the options available 
to overcome renal sufficiency. One of the options discussed 
extensively is the current research on using microencapsu-
lated bacterial cells such as E. coli DH5 to degrade waste 
metabolites such as urea, uric acid, and creatinine among 
others, as an improved therapy of renal failure. The results 
obtained upon oral administration of microencapsulated 
bacterial cells to degrade such waste metabolites in uremia 
are summarized here.
Potential of encapsulated cells  
in renal failure urea removal
Renal insufficiency results in an elevated plasma urea level. 
Several approaches have been suggested to degrade plasma 
urea. In the 1980s, the novel approach of using encapsu-
lated bacteria was shown to be 10 times more efficient in 
degrading urea than oxystarch. One gram of oxystarch was 
found to adsorb only 103.00 mg of urea at pH 7.4 at a urea 
concentration of 0.02 M.5 Thus, to eliminate 40 g of urea 
from 40 L fluid (100 mg/dL urea), 388.34 g of oxystarch 
was required. Microencapsulated genetically engineered 
bacteria were reported to be 30 times more efficient com-
pared to microencapsulated enzyme urease–zirconium 
phosphate. The encapsulated urease–zirconium-phosphate 
system only eliminated 1.60 mg of urea nitrogen or 33.00 mg 
urea/g of microcapsules.5 Therefore, massive quantities of 
microcapsules containing this system were needed to suc-
cessfully remove 40 g of urea from the body.
Certain bacterial cells are reported to be very effec-
tive in lowering BUN levels in vivo. When partially 
nephrectomized rats were orally given B. pasteurii and 
L. sporogenes, the BUN levels were lowered to 62.0 ± 21 and Biologics: Targets & Therapy 2009:3 237
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One can argue about the potential toxicity due to 
the leakage of encapsulated cells during their passage 
through the intestinal tract. In the in vivo studies, the oral 
administration of both free and encapsulated bacteria to 
uremic rats lowered systemic urea from the initial 52.08 
(SD = 2.37) mg/dl to 10.58 (SD = 0.85) mg/dl. However, 
the free E. coli DH5 cells were found to be retained in the 
intestine and when the treatment ceased, the free bacteria 
were still able to lower systemic urea.62 Unlike free bacteria, 
microencapsulated bacteria were excreted in the stool. The 
results showed that, even if all the E. coli DH5 cells leaked 
out, there would be no negative effect on the growth and/or 
survival of the renal failure rats.64 It is reported that uremic 
rats survived longer when they received encapsulated E. coli 
DH5 cells.64,65
Potential of encapsulated cells  
in renal failure ammonia removal
The fate of ammonia during urea removal by daily administration 
of microencapsulated genetically engineered bacteria has 
also been examined. The blood ammonia levels that were 
always present in the range of 539 ± 51 µM decreased 
significantly to 144 ± 24.70 µM.32 In vitro, 40.00 ± 8.60 g 
of APA-encapsulated bacteria have been reported to lower 
ammonia from 975.14 ± 70.15 µM/L to 81.151 ± 7.37 µM/L 
in 30 min.31 The most recent studies in uremic rats also 
showed a reduction of other waste metabolites such as, uric 
acid, creatinine, potassium, and phosphate.55,66,67
Potential of encapsulated cells  
in renal failure creatinine removal
High level of plasma creatinine occurs in renal insufficiency, 
uremia, and other diseases. Serum creatinine levels were 
reported to be lowered in rats fed with B. pasteurii and 
L. sporogenes from 0.9 ± 0.25 mg/dl and 0.9 ± 0.2 mg/dl, 
respectively compared to a previous concentration of 
1.5 ± 0.56 mg/dl. A substantial reduction of approximately 
40% in both groups was observed. These results indicate that 
B. pasteurii and L. sporogenes administered orally as dietary 
supplements metabolize creatinine in vitro.43
Daily administration of microencapsulated genetically 
engineered E. coli DH5 cells have resulted in lowering 
plasma creatinine in vitro and in vivo. Results demonstrated 
that these artificial cells were able to lower plasma creatinine 
in vitro from 21.80 ± 1.10 mg/dl to 19.34 ± 0.60 mg/dl in three 
hours.67 It would be interesting to see if the creatinine levels 
were elevated again upon cessation of the oral treatment.
Potential of encapsulated cells  
in renal failure uric acid removal
Increase in systemic uric acid occurs in renal insufficiency. 
Recently, a proposal was put forth to use artificial cells 
containing microencapsulated genetically engineered E. coli 
DH5 cells for lowering uric acid in vitro and in vivo. Results 
show that genetically engineered bacteria have the ability 
to significantly lower uric acid from 84.80 ± 3.40 mg/dl 
to 9.32 ± 0.05 mg/dl in vitro. They were also capable of 
lowering uric acid levels from the plasma of the experimen-
tal animals from the control levels of 71.00 ± 27.49 mg/dl to 
20.33 ± 17.92 mg/dl in vivo.55 Continued daily oral adminis-
tration reduced the plasma uric acid concentration to normal 
range in uremic rats during the entire test period. Its potential 
in the removal of uric acid may have significance in uremia.
Potential of encapsulated cells  
in removal of other renal failure 
waste metabolites
Lowering of plasma magnesium, phosphate, sodium, chlo-
ride, uric acid, cholesterol, and creatinine is essential in 
uremia and other diseases.5,68 Microencapsulated genetically 
engineered microorganisms have been prepared that can 
remove waste metabolites such as potassium, phosphate, 
magnesium, sodium, chloride, uric acids, cholesterol, creati-
nine, and bilirubin in vitro. This has a significant implication 
in the use of oral microencapsulated genetically engineered 
microorganisms in uremia. These artificial cells were effec-
tive in removing the majority of waste metabolites from the 
plasma as summarized in Table 1. Further studies will reveal 
whether administration of the microencapsulated E. coli 
cells will cause a similar reduction of the above mentioned 
electrolytes and waste metabolites in vivo. This has exciting 
implications for the use of genetically engineered cells in 
a number of medical applications. However, encapsulated 
E. coli DH5 cells could not efficiently remove creatinine 
from the plasma. After 24 hours of incubation with encap-
sulated bacteria, 83.31% ± 2.40% plasma creatinine was 
found remaining.69
All of the uremic metabolites tested, urea, cholesterol, 
uric acid, potassium, phosphate, magnesium, chloride, 
sodium and to a certain extent creatinine, are lowered to 
within normal levels without elevation of ammonia. The 
effectiveness of this approach was explored by studying 
the survival and growth of the renal failure rats receiving 
microcapsules containing genetically engineered E. coli 
DH5 cells. In this respect, untreated uremic control animals Biologics: Targets & Therapy 2009:3 238
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progressively more viable prospect because of the increasing 
advancement in genetic engineering and molecular biology. 
There has been an extensive growth in technical research 
in molecular biology leading to the generation of many 
genetically engineered microorganisms with unique and 
exceptional abilities. Microorganisms have been easily 
manipulated to overproduce enzymes and peptides and 
some have been engineered to metabolize large amounts of 
unwanted metabolites.
Recently, Prakash and Chang31,32,71 have reported oral 
administration of microencapsulated genetically engineered 
E. coli cells containing the Klebsiella aerogenes urease 
gene that causes the overexpression of the urease enzyme 
efficiently removes urea from the reaction media. Micro-
encapsulated genetically engineered E. coli cells have the 
competence of efficiently removing urea without any increase 
in the ammonia levels in the medium.69 Using a single pool 
model, 40 g of microencapsulated genetically engineered 
E. coli cells could lower urea in 40 liters of the body water 
from 100 mg/dl to 1.60 mg/dl within 30 minutes. Also, 
40 g of this microorganism was shown to lower ammonia 
in 40 liters of body water from 758.00 µM/l to 90.42 µM/l 
in as little as 20 minutes. Extrapolated results imply that 
the ability of microencapsulated bacteria to degrade urea 
is adequate to eliminate urea during renal insufficiency.72 
Analogous reductions in blood levels of other metabolites 
have also been reported, implying that the DH5 cells have the 
capacity to regularize levels of several elevated metabolites 
during renal failure.32,58,73 Detailed studies have been done on 
the optimization of procedural parameters for encapsulation 
of bacterial cells in the APA membrane and the profiles of 
genetically engineered microencapsulated bacteria to effec-
tively remove urea and ammonia and the efficacy of urea and 
ammonia removal in vitro.31 In addition to its potential use 
in uremia, the removal of waste metabolites such as urea, 
ammonia, uric acid, bilirubin, and others are also required in 
other medical conditions such as liver failure.43
died during the study period of 21 days, whereas the treated 
animal continued to survive and grew at about the same 
rate as normal animals.64 Another alternative to the oral 
administration of microencapsulated genetically engineered 
cells has been proposed by some researchers: the long-term 
implantation of cells. This can be an effective therapy for 
various conditions but will take numerous years to perfect. 
In the meantime, several researchers are looking into other 
approaches for a more immediate clinical application. For 
example, Aebischer’s group suggested the ingenious use of 
capillary fibers to encapsulate cells that has permitted his 
group to insert these subcutaneously into the cerebrospinal 
fluid on a short-term basis.70 The capsules can be replaced as 
needed,70 and, so far, no immunological sensitivity to the cap-
sules is obvious. This approach evades the problems posed by 
permanent or long-term implantation of microcapsules. The 
oral administration of microencapsulated genetically engi-
neered cells obviates the problems of implantation. However, 
it can be used only for diseases where waste metabolites can 
be eliminated from the gastrointestinal tract, such as in liver 
or kidney failure and in some innate errors of metabolism 
such as phenylketonurea.48 Evidently, the clinical use of 
microencapsulated genetically engineered cells could require 
a combination of different approaches, including implanta-
tion, subcutaneous insertion, and oral administration, to treat 
different conditions.63
Immobilized bacteria have demonstrated an unlimited 
capacity to deplete cholesterol levels in vitro.57 However, 
for practical applications, suitable bacteria with an enhanced 
ability to degrade cholesterol are desirable. There is a strong 
possibility that this method may become accessible in the 
near future with the help of genetic engineering. Research 
in other systems such as using bioencapsulated hepatocytes 
has shown promising results and demonstrated the feasibility 
of using this for cell therapy.57 Further enhancement in 
biocompatibility may allocate this approach to be used 
for cell and gene therapy in humans. This is becoming a 
Table 1 removal of electrolytes by microencapsulated genetically engineered E. coli DH5 cells in vitro69
Metabolites Concentration at 0 hours Concentration at 24 hours
Potassium 5.80 ± 0.40 meq/l 3.50 ± 0.03 meq/l (p  0.001)
Phosphate 2.20 ± 0.9 mg/dl 1.49 ± 0.03 mg/dl (p  0.005)
Magnesium 0.90 ± 0.04 mg/dl 0.66 ± 0.09 mg/dl (p  0.005)
Sodium 172 ± 11.00 meq/l 129 ± 6.12 meq/l (p  0.001)
Chloride 137 ± 6.60 meq/l 107 ± 2.00 meq/l (p  0.005)
Uric acid 84.80 ± 3.40 mg/dl 8.80 ± 3.12 mg/dl (p  0.001)
Cholesterol 1.86 ± 0.10 mmol/l 1.37 ± 0.06 mmol/l (p  0.005)Biologics: Targets & Therapy 2009:3 239
Microorganisms as renal failure biotherapeutics Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
O’Loughlin and colleagues have recently undertaken 
a study to demonstrate the competence of a combination 
of genetically engineered bacteria to lower elevated levels 
of metabolites such as urea and uric acid. Two strains of 
genetically modified bacteria, one expressing enzyme 
‘urease’ to degrade urea and the other expressing enzyme 
‘uricase’ to degrade uric acid, were prepared, combined and 
encapsulated in APA microcapsules for oral administration. 
Within 24 hours, 5 mL of these capsules were capable of 
successfully eliminating 95% of the urea and over 99% of 
the uric acid in vitro from a 100 mL solution formulated to 
mimic the concentration of these solutes in a hemodialysis 
patient.74 This approach could potentially serve in conjunc-
tion to maintenance dialysis in patients with chronic renal 
failure. However, reduction of urea concentration in vivo 
required coadministration of an ion-exchange resin to adsorb 
ammonia. Reduction of uric acid concentration in vivo 
was very efficient and did not require the administering 
Table 2 Potential of using cells as a mode of therapy for renal failure and other diseases
Renal failure markers and disease  
conditions
Cell types Potential mode  
of therapy
Reference
Urea in renal failure, amyotrophic lateral sclerosis Free live E. coli DH5 Oral 58, 62
Microencapsulated genetically 
engineered bacteria
Oral 31, 49, 57, 63, 66, 71, 73, 74
Microencapsulated E. coli DH5 Oral 62
E. coli with Klebsiella aerogenes 
expressing urease
Oral 72
Soil bacteria Oral 41, 42
Encapsulated genetically modified 
xenogenic cells
intrathecal delivery 70
Selected probiotic (B. pasteurii, 
L. sporogenes), ammoniaphilic bacteria
Oral 7, 43, 50





Oral 9, 15, 28, 39
Ammonia in renal failure and liver disease Microencapsulated multienzyme 
complex
Oral 9, 15, 28, 39
Soil bacteria Oral 41, 42
Microencapsulated genetically 
engineered bacteria
Oral 31, 32, 43, 49, 50, 57
Microencapsulated E. coli DH5 Oral 57, 71
Uric acid in renal failure Microencapsulated genetically 
engineered bacteria
Oral 43, 66, 69, 74
Microencapsulated E. coli DH5 Oral 55, 66, 67
Creatinine in renal failure and other diseases Microencapsulated genetically 
engineered bacteria
Oral 66, 69
L. sporogenes, B. pasteurii Oral 43
Microencapsulated E. coli DH5 Oral 55, 66, 67
Other metabolites; potassium/phosphate/ 





Nonprotein nitrogenous compounds in uremia Lyophilized soil bacteria Oral 41, 42
insulin in diabetes Microencapsulated islet cells implantation 43
Serum bilirubin in fulminant hepatic failure rats encapsulated hepatocytes implantation 44–46
Microencapsulated genetically 
engineered microorganisms
Oral administration 43, 55, 66, 67, 69
Toxins and other metabolic wastes in renal, hepatic 
and gastrointestinal diseases
Live selected bacteria: B. pasteurii 
and L. sporogenes
Oral administration 7Biologics: Targets & Therapy 2009:3 240
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of ion-exchange resin. Oral delivery of a combination of 
genetically engineered bacterial cells should be further 
investigated as a valuable accessory to dialysis and/or to 
immunosorption for the treatment of uremia74 in chronic 
kidney failure models.
O’Loughlin and colleagues pioneered the approach of 
using a combination of enzymes in a single delivery vehicle 
to degrade multiple uremic toxins in a nonbacterial system. 
An alginate microcapsule was developed that contained 
three enzymes, urease, uricase, and creatininase, which are 
capable of effectively degrading urea, uric acid, and creati-
nine, respectively, and are significantly elevated in patients 
with renal insufficiency. The microcapsules were evaluated 
both in vitro and in vivo in a rodent model. In vitro, 5 mL of 
the capsules equipped with a few milligrams of the enzymes 
within 24 hours effectively degraded 100% of the uric acid, 
97% of the urea, and 70% of the creatinine in a 100 mL for-
mulated solution that mimicked the concentration of these 
solutes in uremic plasma. In vivo experiments involved a 
chemically induced acute renal failure rat model to evalu-
ate the ability of encapsulated enzymes along with an oral 
sorbent (ion-exchange resin) to degrade uremic toxins.75 
This approach has the potential to be extended to a bacterial 
system and has considerable prospect of being to be used in 
conjunction therapy in the treatment of ESRD.
Oral administration of encapsulated 
cells live cells as potential renal 
failure kidney substitute
It has recently been demonstrated that daily oral administra-
tion of artificial cells microcapsule containing a genetically 
engineered microorganism has potential as a renal failure 
kidney substitute. Furthermore, these genetically modified 
bacteria also have the ability to remove potassium, phosphate, 
uric acid, and other waste metabolites from uremic plasma. 
Future research may lead to the efficient and effective use 
of microencapsulated genetically modified bacteria as thera-
peutic agents.58
The accessibility of an oral bacterial therapy has the 
potential to save over 400,000 lives worldwide each year. 
Research has demonstrated that these microencapsulated 
genetically engineered bacteria are much more successful in 
removing ammonia than any method currently available.31,32,75 
If further detailed investigation convinces us about the 
efficacy and safety of this approach for urea removal, it 
might be possible to use this technology to remove waste 
metabolites such as urea, ammonia, creatinine, and uric acid 
in uremic patients with chronic renal failure. Because of 
these encouraging results, further research will concentrate 
on experimental design to use the concept of oral administra-
tion of genetically engineered bacterial cells in combination 
with other technologies for in vivo use. Thus, this approach 
will complete the currently available oral therapy for uremia 
using adsorbents, ion-exchange resins, and osmotic agents. 
The oral administration approach might therefore also be 
applicable for the removal of ammonia in other diseases such 
as chronic liver failure.
The use of microencapsulated bacterial cells has potential 
application not only in renal insufficiency, innate errors of 
urea metabolism, but also in liver insufficiency and gastro-
intestinal disorders and diseases.43 The feasibility of oral 
administration of polymeric artificial cells containing geneti-
cally engineered cells for the specific removal of undesirable 
amino acids in some innate errors of metabolism as in phe-
nylketonurea48 has been reported. Further detailed studies on 
efficacy and safety are required before this promising new 
approach can be fully recognized and applied.
Microencapsulated genetically modified cells can be 
administered orally to a subject with uremia to alleviate the 
symptoms of uremia. Depending on the extent of renal dam-
age in the patient suffering from uremia, with this oral therapy 
the patient either will not require dialysis, require dialysis less 
frequently, and for shorter periods, or maybe will not require 
initiation of dialysis as early as would be needed without 
treatment. In initial stages of ESRD, before fluid retention, 
genetically modified bacterial cells can be administered 
orally alone. However, in later stages with fluid retention in 
patients, the oral approach could be combined with minute 
quantities of an oral osmotic agent such as mannitol,24 to 
remove about a liter of fluid per day. Recent demonstrations 
have implied that daily dialysis avoids large fluctuations in 
the systemic waste metabolites. This oral approach could 
be used as in combination with standard dialysis to prevent 
large fluctuations in the systemic waste metabolites. The 
swift and proficient removal of uric acid may have added 
potential applications in hyperuricemia, such as in gout and 
in chemotherapy.66 Future studies will unveil the potential use 
of encapsulated genetically engineered bacteria for removal 
of urea and ammonia in biotechnology, chemical engineering, 
and biomedical applications.31
Will a combination of microencapsulated E. coli DH5 
cells to deplete urea, and oral adsorbents and osmotic agents 
to regulate water, electrolytes, and other uremic waste 
metabolites remove the need for dialysis entirely in patients 
with kidney failure?63 Will the oral administration of these Biologics: Targets & Therapy 2009:3 241
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genetically modified bacterial cells to uremic patients result 
in decreased frequency of dialysis or perhaps even decreased 
dialysis treatment times?51 Further research could conceiv-
ably produce an alternative treatment of chronic renal failure 
and provide an insight for the future direction of this emergent 
and highly prospective technology. This also has potential 
applications in cell and gene therapy.57
Conclusion
Kidney failure leads to uremia, a complicated syndrome 
associated with increased levels of unwanted metabolites 
and electrolytes.3–5 It becomes essential to remove waste 
metabolites and regulate water and electrolytes in patients 
with renal insufficiency. Standard treatment by dialysis or 
transplantation is very effective but is extremely expensive and 
unaffordable by the majority of the world. Researchers of other 
approaches including absorbents, are faced with one major 
challenge, the need to remove large amounts of urea, ammonia, 
and other waste metabolites and electrolytes.4–6,16,19,22,23,28,76 
Currently, artificial cells are being investigated with great 
optimism for use in the replacement of cell and even organ 
functions, especially related to metabolic functions in the 
treatment of diseases such as diabetes, liver failure, and 
kidney failure. When artificial microencapsulated cells are 
given by implantation,13,36,77–80 The problem of retention in the 
body is eliminated due to the use of polymeric membranes. 
Orally administered microencapsulated live cells warrants 
investigation as a supplement to the routine dialysis system 
to avert large fluctuations in the systemic waste metabolites 
and electrolytes. Further detailed analysis, particularly on 
safety studies are vital. If proven safe, this approach of using 
microencapsulated live cells will be an economical means 
for managing renal failure redundant waste metabolites and 
electrolytes.
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